Table.
Summary description of molecular subtypes of medulloblastoma
Molecular Subtype | Approximate percent of patients | Typical patient age | Typical Histology | Cytogenetic markers | Molecular markers | Clinical strategy |
---|---|---|---|---|---|---|
WNT | 10% | Older childhood | Classic | Monosomy 6 | Beta-catenin | Reduction in therapy |
SHH | 25% | Infant and Adult | Desmoplastic or Classic | 9q loss | SFRP1[47]or GAB1[50] | SHH pathway inhibitors |
Group C | 30% | Childhood | Classic or Anaplastic | Isochromosome 17q | MYC activation in 50% of this subtype | Intensified therapy, novel therapeutics |
Group D | 35% | Childhood | Classic or Anaplastic | Isochromosome 17q | Unknown | Research focus needed |